5LGH image
Entry Detail
PDB ID:
5LGH
Keywords:
Title:
Afamin antibody fragment, N14 Fab, L1- glycosilated, crystal form II, same as 5L7X, but isomorphous setting indexed same as 5L88, 5L9D
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2016-07-07
Release Date:
2016-08-03
Method Details:
Experimental Method:
Resolution:
1.86 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:MOUSE ANTIBODY FAB FRAGMENT, IGG1-KAPPA HEAVY CHAIN
Chain IDs:A (auth: H)
Chain Length:220
Number of Molecules:1
Biological Source:MUS MUSCULUS
Polymer Type:polypeptide(L)
Description:MOUSE ANTIBODY FAB FRAGMENT, IGG1-KAPPA LIGHT CHAIN
Chain IDs:B (auth: L)
Chain Length:215
Number of Molecules:1
Biological Source:MUS MUSCULUS
Primary Citation
The N14 anti-afamin antibody Fab: a rare VL1 CDR glycosylation, crystallographic re-sequencing, molecular plasticity and conservative versus enthusiastic modelling.
Acta Crystallogr D Struct Biol 72 1267 1280 (2016)
PMID: 27917827 DOI: 10.1107/S205979831601723X

Abstact

The monoclonal antibody N14 is used as a detection antibody in ELISA kits for the human glycoprotein afamin, a member of the albumin family, which has recently gained interest in the capture and stabilization of Wnt signalling proteins, and for its role in metabolic syndrome and papillary thyroid carcinoma. As a rare occurrence, the N14 Fab is N-glycosylated at Asn26L at the onset of the VL1 antigen-binding loop, with the α-1-6 core fucosylated complex glycan facing out of the L1 complementarity-determining region. The crystal structures of two non-apparent (pseudo) isomorphous crystals of the N14 Fab were analyzed, which differ significantly in the elbow angles, thereby cautioning against the overinterpretation of domain movements upon antigen binding. In addition, the map quality at 1.9 Å resolution was sufficient to crystallographically re-sequence the variable VL and VH domains and to detect discrepancies in the hybridoma-derived sequence. Finally, a conservatively refined parsimonious model is presented and its statistics are compared with those from a less conservatively built model that has been modelled more enthusiastically. Improvements to the PDB validation reports affecting ligands, clashscore and buried surface calculations are suggested.

Legend

Protein

Chemical

Disease

Primary Citation of related structures